Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more
Structure Therapeutics Inc. American Depositary Shares (GPCR) - Net Assets
Latest net assets as of December 2025: $1.52 Billion USD
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has net assets worth $1.52 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.58 Billion) and total liabilities ($67.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.52 Billion |
| % of Total Assets | 95.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.8 |
Structure Therapeutics Inc. American Depositary Shares - Net Assets Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual net assets of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.52 Billion | +75.34% |
| 2024-12-31 | $864.84 Million | +90.93% |
| 2023-12-31 | $452.97 Million | +493.40% |
| 2022-12-31 | $-115.14 Million | -77.86% |
| 2021-12-31 | $-64.73 Million | -188.11% |
| 2020-12-31 | $-22.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Structure Therapeutics Inc. American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44735400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.00K | 0.00% |
| Other Comprehensive Income | $1.05 Million | 0.07% |
| Other Components | $1.99 Billion | 130.94% |
| Total Equity | $1.52 Billion | 100.00% |
Structure Therapeutics Inc. American Depositary Shares Competitors by Market Cap
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Union Bank of India
NSE:UNIONBANK
|
$3.87 Billion |
|
Solar Industries India Limited
NSE:SOLARINDS
|
$3.87 Billion |
|
MERLIN Properties SOCIMI S.A
PINK:MRPRF
|
$3.87 Billion |
|
Tanger Factory Outlet Centers Inc
NYSE:SKT
|
$3.87 Billion |
|
REINET INVESTMENTS S.C.A.
F:RNT
|
$3.87 Billion |
|
Colliers International Group Inc
F:FSV
|
$3.86 Billion |
|
Allreal Holding AG
LSE:0QPD
|
$3.86 Billion |
|
Pegasystems Inc
NASDAQ:PEGA
|
$3.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Structure Therapeutics Inc. American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 864,843,000 to 1,516,377,000, a change of 651,534,000 (75.3%).
- Net loss of 141,202,000 reduced equity.
- New share issuances of 665,708,000 increased equity.
- Other comprehensive income increased equity by 140,000.
- Other factors increased equity by 126,888,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-141.20 Million | -9.31% |
| Share Issuances | $665.71 Million | +43.9% |
| Other Comprehensive Income | $140.00K | +0.01% |
| Other Changes | $126.89 Million | +8.37% |
| Total Change | $- | 75.34% |
Book Value vs Market Value Analysis
This analysis compares Structure Therapeutics Inc. American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.61 | $56.15 | x |
| 2021-12-31 | $-1.77 | $56.15 | x |
| 2022-12-31 | $-3.15 | $56.15 | x |
| 2023-12-31 | $12.33 | $56.15 | x |
| 2024-12-31 | $16.43 | $56.15 | x |
| 2025-12-31 | $25.62 | $56.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Structure Therapeutics Inc. American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-9.31%) is below the historical average (-7.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $2.23 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.53 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.81 Million |
| 2023 | -19.79% | 0.00% | 0.00x | 1.06x | $-134.92 Million |
| 2024 | -14.17% | 0.00% | 0.00x | 1.04x | $-209.01 Million |
| 2025 | -9.31% | 0.00% | 0.00x | 1.04x | $-292.84 Million |
Industry Comparison
This section compares Structure Therapeutics Inc. American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.52 Billion | 0.00% | 0.04x | $3.87 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |